Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

777 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G; GIMEMA CML Working Party. Castagnetti F, et al. Among authors: baccarani m. Am J Hematol. 2017 Aug;92(8):797-805. doi: 10.1002/ajh.24774. Epub 2017 May 30. Am J Hematol. 2017. PMID: 28466557 Free article.
Interferon-alfa for chronic myeloid leukemia.
Baccarani M, Russo D, Rosti G, Martinelli G. Baccarani M, et al. Semin Hematol. 2003 Jan;40(1):22-33. doi: 10.1053/shem.2003.50004. Semin Hematol. 2003. PMID: 12563609 Review.
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib.
Soverini S, Martinelli G, Amabile M, Poerio A, Bianchini M, Rosti G, Pane F, Saglio G, Baccarani M; Italian Cooerative Study Group on Chronic Myeloid Leukemia; European LeukemiaNet-6th Framework Program of the European Community. Soverini S, et al. Among authors: baccarani m. Clin Chem. 2004 Jul;50(7):1205-13. doi: 10.1373/clinchem.2004.031112. Epub 2004 Apr 23. Clin Chem. 2004. PMID: 15107311
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, Testoni N, Abruzzese E, Montefusco E, Ottaviani E, Iuliano F, Russo D, Gobbi M, Alimena G, Martino B, Terragna C, Pane F, Saglio G, Baccarani M, Martinelli G. Iacobucci I, et al. Among authors: baccarani m. J Clin Oncol. 2006 Jan 20;24(3):454-9. doi: 10.1200/JCO.2005.03.2011. J Clin Oncol. 2006. PMID: 16421422
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia. Iacobucci I, et al. Among authors: baccarani m. Clin Cancer Res. 2006 May 15;12(10):3037-42. doi: 10.1158/1078-0432.CCR-05-2574. Clin Cancer Res. 2006. PMID: 16707599 Clinical Trial.
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia. Soverini S, et al. Among authors: baccarani m. Clin Cancer Res. 2006 Dec 15;12(24):7374-9. doi: 10.1158/1078-0432.CCR-06-1516. Clin Cancer Res. 2006. PMID: 17189410
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party.
Rosti G, Iacobucci I, Bassi S, Castagnetti F, Amabile M, Cilloni D, Poerio A, Soverini S, Palandri F, Rege Cambrin G, Iuliano F, Alimena G, Latagliata R, Testoni N, Pane F, Saglio G, Baccarani M, Martinelli G. Rosti G, et al. Among authors: baccarani m. Haematologica. 2007 Jan;92(1):101-5. doi: 10.3324/haematol.10239. Haematologica. 2007. PMID: 17229641 Free article. Clinical Trial.
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N, Soverini S, Castagnetti F, De Vivo A, Breccia M, Specchia G, Abruzzese E, Martino B, Cilloni D, Saglio G, Pane F, Liberati AM, Rosti G, Baccarani M; GIMEMA Working Party on CML. Palandri F, et al. Among authors: baccarani m. J Clin Oncol. 2008 Jan 1;26(1):106-11. doi: 10.1200/JCO.2007.13.2373. J Clin Oncol. 2008. PMID: 18165644
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.
Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T, Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; GIMEMA Working Party on CML. Palandri F, et al. Among authors: baccarani m. Haematologica. 2008 May;93(5):770-4. doi: 10.3324/haematol.12265. Epub 2008 Mar 26. Haematologica. 2008. PMID: 18367490 Free article. Clinical Trial.
777 results